<DOC>
	<DOC>NCT01434186</DOC>
	<brief_summary>To evaluate the efficacy, safety, tolerability, of Saxagliptin (BMS-477118) in combination with Metformin in pediatric patients with type 2 diabetes</brief_summary>
	<brief_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone</brief_title>
	<detailed_description>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone or in Combination with Baseline Insulin Therapy</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male and female patients eligible if 10 years of age, up to 17 years and 30 weeks of age at the time of screening Previously diagnosed as having type 2 diabetes HbA1c ≥7.0% and ≤10.5% Body weight ≥ 30 kg Stable dose of metformin (≥ 1000mg ≤ 2000mg) for a minimum of 2 months Women must have a negative serum or urine pregnancy test Women must not be breastfeeding Current use of antidiabetic medications or use within the specified timeframe prior to screening (Exception: Metformin) Fasting plasma glucose (FPG) &gt; 255 mg/dL Diabetic ketoacidosis (DKA) within 6 months of study entry Abnormal renal function Active liver disease Anemia An abnormal Thyroid Stimulating Hormone (TSH) Creatinine kinase (CK) ≥ 3X ULN</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>